My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 269

    1.

    Introduction: severe sepsis and drotrecogin alfa (activated).

    Artigas A, Martin CD.

    Crit Care. 2007;11 Suppl 5:S1. No abstract available. PMID: 18269688 [PubMed - indexed for MEDLINE]Related articles

    2.

    Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

    Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, Takano JS, Martin LD, Quint P, Yeh TS, Dalton HJ, Gessouron MR, Brown KE, Betts H, Levin M, Macias WL, Small DS, Wyss VL, Bates BM, Utterback BG, Giroir BP.

    Pediatrics. 2004 Jan;113(1 Pt 1):7-17.PMID: 14702440 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Drotrecogin alfa (activated) in the treatment of severe sepsis.

    Vincent JL.

    Expert Rev Anti Infect Ther. 2006 Aug;4(4):537-47. Review.PMID: 17009934 [PubMed - indexed for MEDLINE]Related articles

    4.

    Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.

    Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J.

    Crit Care Med. 2005 Oct;33(10):2266-77.PMID: 16215381 [PubMed - indexed for MEDLINE]Related articles

    5.

    Clinical trials in severe sepsis with drotrecogin alfa (activated).

    Laterre PF.

    Crit Care. 2007;11 Suppl 5:S5. Review.PMID: 18269692 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    The development of drotrecogin alfa (activated) for the treatment of severe sepsis.

    Macias WL, Yan SB, Grinnell BW.

    Int J Artif Organs. 2004 May;27(5):360-70. Review. No abstract available. PMID: 15202813 [PubMed - indexed for MEDLINE]Related articles

    7.

    Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.

    [No authors listed]

    Prescrire Int. 2007 Feb;16(87):7-9.PMID: 17323514 [PubMed - indexed for MEDLINE]Related articles

    8.

    Mechanism of action of drotrecogin alfa activated (rhAPC).

    Jilma B, Derhaschnig U.

    Thromb Haemost. 2004 May;91(5):1050. No abstract available. PMID: 15116270 [PubMed - indexed for MEDLINE]Related articles

    9.

    Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.

    Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G 3rd, Kinasewitz GT; PROWESS Sepsis Study Group.

    Thromb Haemost. 2003 Oct;90(4):642-53.PMID: 14515185 [PubMed - indexed for MEDLINE]Related articles

    10.

    Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis.

    Dhainaut JF.

    Am J Surg. 2002 Dec;184(6A Suppl):S5-10. Review. No abstract available. PMID: 12521612 [PubMed - indexed for MEDLINE]Related articles

    11.

    [Hemorrhagic risk of drotrecogin alfa (activated) in severe sepsis]

    Perrotin D.

    Ann Fr Anesth Reanim. 2003 Dec;22 Spec No 1:16-9. French. No abstract available. PMID: 15359934 [PubMed - indexed for MEDLINE]Related articles

    12.

    Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

    De Backer D.

    Drug Saf. 2007;30(11):995-1010. Review.PMID: 17973539 [PubMed - indexed for MEDLINE]Related articles

    13.

    Drotrecogin alfa: a role in emergency department treatment of severe sepsis?

    McLeay AM.

    Emerg Med Australas. 2004 Aug;16(4):324-35. Review.PMID: 15283720 [PubMed - indexed for MEDLINE]Related articles

    14.

    Drotrecogin alfa (activated) in the treatment of severe sepsis.

    Vincent JL.

    Curr Drug Saf. 2007 Sep;2(3):227-31. Review.PMID: 18690972 [PubMed - indexed for MEDLINE]Related articles

    15.

    Drotrecogin alfa (activated) in severe sepsis.

    LaRosa SP.

    N Engl J Med. 2006 Jan 5;354(1):94-6; author reply 94-6. No abstract available. PMID: 16395833 [PubMed - indexed for MEDLINE]Related articles

    16.

    Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death.

    Williams MD, Janes JM, Nelson DR.

    Crit Care. 2006;10(5):424. No abstract available. PMID: 17094791 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Drotrecogin alfa (activated) in severe sepsis.

    Baillie JK, Murray G.

    N Engl J Med. 2006 Jan 5;354(1):94-6; author reply 94-6. No abstract available. PMID: 16395834 [PubMed - indexed for MEDLINE]Related articles

    18.

    Comment on "Drotrecogin Alfa (activated) (recombinant human protein C, rhAPC) reduces host coagulopathy response in patients with severe sepsis".

    Taylor F Jr.

    Thromb Haemost. 2003 Oct;90(4):560-1. No abstract available. PMID: 14515171 [PubMed - indexed for MEDLINE]Related articles

    19.

    Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

    Weiss KD.

    Pediatrics. 2004 Jan;113(1 Pt 1):134. No abstract available. PMID: 14702464 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    A case series of drotrecogin alfa (activated) in lung transplant recipients.

    Daniels TL, Dummer JS, Bernard GR, Milstone AP.

    Transplantation. 2006 Jun 27;81(12):1739-42.PMID: 16794542 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity